Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74266 | 1.00 | NFE2L2 (0.56) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL29190717 | 0.82 | NFE2L2 (0.50) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL700052 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL13766558 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL13766470 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL22468800 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL700051 | 0.82 | NFE2L2 (0.78) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL20597936 | 0.77 | — | — | |
| SCHEMBL9970459 | 0.77 | NFE2L2 (0.62) | NFE2L2HSD11B1PTGS1APPFBP1 | |
| SCHEMBL17862090 | 0.74 | NFE2L2 (0.59) | NFE2L2HSD11B1PTGS1APPFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515969-B1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2010-08-25 | — | — | EP | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| CN-114656380-B | Method for simply synthesizing allyl thiomethyl ether | 南阳师范学院 | 2023-06-02 | — | — | CN | disclosed |
| CN-114656380-A | Method for simply synthesizing allyl methyl sulfide | 南阳师范学院 | 2022-06-24 | — | — | CN | disclosed |
| EP-1515969-B2 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LTD (GB) | 2017-10-11 | — | — | EP | disclosed |
| US-9686990-B2 | Spiroindolinepiperidine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | SYNGENTA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9174987-B2 | Spiroindolinepiperidine derivatives | SYNGENTA LIMITED (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9045422-B2 | Piperidine derivatives with pesticidal properties | SYNGENTA PARTICIPATIONS AG (CH) | 2015-06-02 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| EP-0459285-B1 | Ortho-substituted benzyl esters of cyclopropane carboxylic acids | BASF AG (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-5371268-A | Ortho-substituted benzyl esters of cyclopropanecarboxylic acids | BASF AKTIENGESELLSCHAFT (DE) | 1994-12-06 | — | — | US | disclosed |
| EP-0459285-A1 | Ortho-substituted benzyl esters of cyclopropane carboxylic acids | BASF Aktiengesellschaft (DE) | 1991-12-04 | — | — | EP | disclosed |
| US-5053070-A | PYRIMIDINE DERIVATIVES, PREPARATION PROCESSES THEREOF, HERBICIDE CONTAINING THE SAME, AND HERBICIDAL COMPOSITIONS CONTAINING THE SAME ALONG WITH OTHER ACTIVE INGREDIENT | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-10-01 | — | — | US | disclosed |
| US-4986846-A | PRE-AND POSTEMERGENCE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0374839-A1 | 2-(4,6-Dimethoxy-2-pyrimidinyloxy)benzaldoximes, preparation processes thereof, herbicides containing the same, and herbicidal compositions containing the same along with other active ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-06-27 | — | — | EP | disclosed |
| US-4249027-A | Process for the preparation of 5-substituted resorcinols and related intermediates | CIBA-GEIGY CORPORATION (US) | 1981-02-03 | — | — | US | disclosed |
| US-4020098-A | Process for the preparation of 5-substituted resorcinols and related intermediates | CIBA-GEIGY CORPORATION (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | NFE2L2 4595/4885HSD11B1 2188/4885PTGS1 1005/4885 |
| US-20160007608-A1 | SPIROINDOLINEPIPERIDINE DERIVATIVES | RECQL, OPRD1, SKP1 | NFE2L2 693/4885HSD11B1 4136/4885PTGS1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.